Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 7Rectal Neoplasms 7Oropharyngeal Neoplasms 7Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 3Lung Neoplasms 3Hypopharyngeal Neoplasms 3Glioblastoma 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Radiation Injuries 2Pathologic Complete Response 2Nasopharyngeal Carcinoma 2Mouth Neoplasms 2Laryngeal Neoplasms 2Vaginal Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Tobacco Use Disorder 1Thymoma 1Smoking Cessation 1Smoking 1Small Cell Lung Carcinoma 1Sinonasal undifferentiated carcinoma 1Sinonasal Squamous Cell Carcinoma 1Resectable Esophageal Cancer 1Rectal Malignant Neoplasms 1Postoperative Complications 1

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Chemoradiotherapy × 1 year × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡